InflaRx Amends Agreement for Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

 

• InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in China
• STS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s technology in-licensed by STS
• InflaRx will receive 10% royalties on net sales of BDB-001 for the treatment of COVID-19 in China
• STS to make an additional USD 2.5 million investment in InflaRx at a price of USD 5.00 per share
• Option for InflaRx to request STS makes a further USD 7.5 million investment in InflaRx

https://www.biospace.com/article/releases/inflarx-announces-amendment-of-co-development-agreement-and-additional-equity-investment-by-staidson-in-connection-with-regulatory-filing-in-china-for-anti-c5a-antibody-for-treatment-of-covid-19/